vyzulta
  • Efficacy Results
    • Study Design
    • Primary Endpoints
    • Secondary Endpoints
  • Mechanism of Action
    • Two Routes
    • Metabolism
  • Safety Profile
  • Dosing And Administration
  • Summary
  • Resources And References
  • switch to english language
  • EN
  • FR
  • Efficacy Results
    ▼
    • Study Design
    • Primary Endpoints
    • Secondary Endpoints
  • Mechanism of Action
    ▼
    • Two Routes
    • Metabolism
  • Safety Profile
  • Dosing And Administration
  • Summary
  • Resources And References

PrVYZULTATM (latanoprostene bunod ophthalmic solution, 0.024% w/v) is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.1

GO TO EFFICACY PROFILE >
GO TO SAFETY PROFILE >
  • Important Safety Information
  • Contact us
  • Legal Notice & Privacy Policy

Logo

Bausch + Lomb Corporation
TM is a trademark of Bausch & Lomb Incorporated or its affiliates.
© Bausch + Lomb Corporation
VYZ.0018.CA.23-EN

VYZULTA
HCP – Home

Important Safety Information

Clinical use:

Pediatrics (≤16 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

Geriatrics (≥65 years of age): Evidence from clinical studies and experience suggests that safety and effectiveness is comparable between elderly and other adult patients.

Relevant warnings and precautions:

  • Bacterial keratitis
  • Gradual change in the eyelashes and vellus hair in the treated eye. These changes include increased length, thickness, and the number of lashes or hairs. Eyelash changes are usually reversible upon discontinuation of treatment.
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis) and should generally not be used in patients with active intraocular inflammation
  • Use with caution in patients who do not have an intact posterior capsule or who have known risk factors for macular edema
  • May cause changes to pigmented tissues
  • Contact lenses should be removed prior to the administration of VYZULTA™ because this product contains benzalkonium chloride. Lenses may be reinserted after 15 minutes following administration.
  • Use with caution in patients with a history of herpetic keratitis and do not use in cases of active herpes simplex keratitis and in patients with a history of recurrent herpetic keratitis specifically associated with prostaglandin analogues
  • Use with caution in patients with hepatic and renal impairment
  • Use with caution in patients with severe or uncontrolled asthma
  • Should not be used in pregnant women unless the benefit to the mother justifies the potential risk to the fetus
  • Caution when administered to nursing women

For more information:

Please consult the Product Monograph at https://EN_Updated-Vyzulta-PM-E-2023-07-27_-1.pdf for important information relating to adverse reactions, drug interactions, and dosing information that has not been discussed in this piece. The Product Monograph is also available by calling 1-888-459-5000.

Continue